Palbociclib is a drug manufactured by Pfizer, marketed under the brand Ibrance, and it is used for the treatment of hormone receptor-positive (HR+ve) and human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer. It inhibits the activity of cyclin dependent kinases, specifically CDK4 and CDK8, thus preventing the growth of cancer cells.
This report contains market size and forecasts of Palbociclib Drug in Global, including the following market information:
Global Palbociclib Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Palbociclib Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tablets Type Palbociclib Drug Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Palbociclib Drug include Pfizer, Beacon Pharmaceuticals, Incepta Pharmaceuticals, Bluepharma and NANO DARU, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Palbociclib Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Palbociclib Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Palbociclib Drug Market Segment Percentages, by Type, 2021 (%)
Tablets Type Palbociclib Drug
Capsules Type Palbociclib Drug
Global Palbociclib Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Palbociclib Drug Market Segment Percentages, by Application, 2021 (%)
Hospitals
Diagnostic Centers
Research Institutes
Global Palbociclib Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Palbociclib Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Palbociclib Drug revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Palbociclib Drug revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Beacon Pharmaceuticals
Incepta Pharmaceuticals
Bluepharma
NANO DARU